Delving into the Latest Updates on Ibuprofen with Synapse

Overview

Basic Info

SummaryIbuprofen, a small molecule drug, functions as a COX inhibitor. Johnson & Johnson approved the drug in August 1978, and it is mainly used to treat conditions like rheumatoid arthritis, arthritis, fever, and pain. Ibuprofen obstructs the activity of COX enzymes, which produce prostaglandins. These hormones are involved in inflammation and pain signaling. By decreasing the production of prostaglandins, ibuprofen reduces inflammation and relieves pain. Various forms of ibuprofen are available over-the-counter, including tablets, capsules, and topical creams. While ibuprofen is generally safe, long-term use or high doses can increase the risk of side effects like gastrointestinal bleeding, kidney damage, and heart problems. Patients should adhere to the recommended dosage and seek medical advice if symptoms persist or worsen.

Drug Type

Small molecule drug

Synonyms

(4-isobutylphenyl)-α-methylacetic acid, (RS)-ibuprofen, (±)-2-(p-isobutylphenyl)propionic acid

+ [99]

Target

CAIX x COX-1 x COX-2

Action

inhibitors

Mechanism

CAIX inhibitors(Carbonic anhydrase IX inhibitors), COX-1 inhibitors(Cyclooxygenase-1 inhibitors), COX-2 inhibitors(Cyclooxygenase-2 inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesNervous System Diseases+ [9]

Active Indication

Acute PainArthritis PainBack Pain+ [31]

Inactive Indication

Acute low back painAnalgesiaAnkle Injuries+ [15]

Originator Organization

Johnson & Johnson

Active Organization

Strides Pharma Science Ltd.Recordati Rare Diseases, Inc.

Shenyang Shuangding Pharmaceutical Co., Ltd.

+ [20]

Inactive Organization

Pfizer Inc.

Laboratório Teuto Brasileiro SA

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

+ [17]

License Organization

Apotex, Inc.

Zhejiang Medical Technology Development Co., Ltd.

Avecho Biotechnology Ltd.

+ [5]

Drug Highest PhaseApproved

First Approval Date

China (01 Jan 1966),

ArthritisFeverPain

RegulationPriority Review (China), Orphan Drug (South Korea)

Login to view timeline

Structure/Sequence

Molecular FormulaC13H18O2

InChIKeyHEFNNWSXXWATRW-UHFFFAOYSA-N

CAS Registry15687-27-1

Suzetrigine is a selective NaV1.8 inhibitor that provides peripheral analgesia without opioid-related CNS effects. This single-center stepped-wedge randomized clinical trial evaluates whether a suzetrigine-based postoperative analgesic regimen provides non-inferior pain control compared with standard opioid-inclusive care following transvaginal pelvic reconstructive surgery. The study will enroll 120 participants and assess pain, opioid consumption, adverse events, and functional recovery.

Start Date01 Nov 2026

Sponsor / Collaborator

University of California, Los Angeles

NCT07512297

/ Not yet recruitingPhase 4IIT

Comparative Evaluation of Non-Opioid Analgesics for Pain Control During Extracorporeal Shock Wave Lithotripsy: A Prospective Randomized Controlled Trial

This prospective randomized controlled trial aims to compare the analgesic efficacy of three non-opioid analgesics (ibuprofen, paracetamol, and tenoxicam) during extracorporeal shock wave lithotripsy (ESWL). All patients undergoing ESWL will be randomly assigned into four groups including a placebo group.
Pain intensity will be assessed using the Visual Analog Scale (VAS) at the 5th, 10th, 15th, and 20th minutes during the procedure. In addition to comparing analgesic efficacy, the study will evaluate patient-related and stone-related factors affecting pain perception, including body mass index, subcutaneous fat thickness, and stone density measured by Hounsfield Units.
The study also aims to assess the relationship between analgesic efficacy, energy levels applied during ESWL, and treatment outcomes such as stone-free rates. The findings may contribute to optimizing individualized pain management strategies and improving treatment efficiency in ESWL procedures.

Start Date01 Oct 2026

Sponsor / Collaborator

Gaziantep University of

NCT07766330

/ Not yet recruitingNot ApplicableIIT

Effect of Nonsteroidal Anti-Inflammatory Drug Restriction on the Efficacy of Platelet-Rich Plasma in Knee Osteoarthritis

The goal of this randomized clinical trial is to learn whether taking ibuprofen, a nonsteroidal anti-inflammatory drug, after a platelet-rich plasma (PRP) injection changes pain relief and knee function in adults with knee osteoarthritis.
The main questions it aims to answer are:
Does ibuprofen change the improvement in knee pain six months after a PRP injection compared with acetaminophen?
Does ibuprofen change knee function or the need for additional pain medicine during follow-up?
Researchers will compare PRP followed by ibuprofen with PRP followed by acetaminophen. Participants will receive one ultrasound-guided PRP injection and take the assigned medication every eight hours for five days. They will complete assessments of pain, knee function, additional pain medicine use, and safety. Participants and the physician performing the injection will not know which medication was assigned.

Start Date01 Oct 2026

Sponsor / Collaborator

Universidade Federal De Sao Paulo

100 Clinical Results associated with Ibuprofen

Login to view more data

100 Translational Medicine associated with Ibuprofen

Login to view more data

100 Patents (Medical) associated with Ibuprofen

Login to view more data

23,964

Literatures (Medical) associated with Ibuprofen

31 Dec 2026·ANNALS OF MEDICINE

Targeting CXCL8 in post-traumatic stress disorder and Alzheimer’s disease: insights from cross-disorder molecular analysis

Article

Author: Li, Xia ; Cao, Zixuan ; Li, Tianjing ; Liao, Dan ; Zhang, Zhuoyuan ; Li, Xin ; Zhang, Min ; Luo, Peng ; Tian, Zhicheng ; Liu, Dan ; Yang, Qiuzi

BACKGROUND:

Emerging clinical evidence indicates that post-traumatic stress disorder (PTSD) may accelerate Alzheimer's disease progression, yet the molecular mechanisms linking these disorders remain poorly understood.

METHODS:

We conducted an integrative bioinformatics analysis combining blood cell profiles from PTSD and Alzheimer's disease cohorts to identify shared pathogenic pathways and therapeutic targets. Computational drug repositioning and experimental validation were used to pinpoint effective treatments.

RESULTS:

Our analysis revealed convergent dysregulation in neuroimmune and metabolic pathways, including compensatory upregulation of terpenoid biosynthesis and impaired JAK-STAT neuroprotective signaling. Cross-disorder network analysis identified CXCL8 as a central hub gene, prioritized through network pharmacology and machine learning. Mechanistic studies demonstrated that CXCL8 is dually regulated by stress-responsive transcriptional activators and neurodegeneration-associated microRNAs, positioning it as a key mediator of peripheral-central immune crosstalk. Immunoassays further linked CXCL8 to T cell recruitment (γδ T, CD8⁺ T), suggesting its role in sustaining neuroinflammation common to both diseases. Among potential therapeutics, nonsteroidal anti-inflammatory drugs emerged as modulators of CXCL8-driven pathology, with ibuprofen significantly suppressing neurodegeneration-associated CXCL8 overexpression.

CONCLUSIONS:

Our findings highlight CXCL8-mediated neuroimmune dysregulation as a critical link between PTSD and Alzheimer's disease, supporting targeted anti-inflammatory strategies to mitigate stress-related dementia risk. This study advances a precision medicine framework for neurodegenerative comorbidities by integrating cross-disease molecular signatures.

31 Dec 2026·Bioengineered

Statement of Retraction: Ibuprofen promotes p75 neurotrophin receptor expression through modifying promoter methylation and N6-methyladenosine-RNA-methylation in human gastric cancer cells

Article

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Ibuprofen and nimesulide derivatives selectively induce apoptosis in HER2-positive breast cancer via inhibition of the PLA₂–COX-2–NF-κB pathway

Article

Author: Bedir, İpek ; Küçükgüzel, Ş Güniz ; Çakırlı, Egemen ; Biliz, Yağmur ; Telci, Dilek ; Yılmaz, Özgür

Abstract:

Background:

Chronic inflammation contributes to breast cancer development through the phospholipase A₂ (PLA₂)–cyclooxygenase-2 (COX-2)–nuclear factor κB (NF-κB) cascade, which regulates prostaglandin synthesis, oxidative stress, and transcription of pro-inflammatory and anti-apoptotic genes. This pathway is particularly active in HER2-positive breast cancer, promoting proliferation, invasion, and resistance to apoptosis. Non-steroidal anti-inflammatory drugs such as ibuprofen and nimesulide target COX enzymes and have shown potential in suppressing inflammation-driven tumorigenesis. In this study, we evaluated the anticancer and anti-inflammatory activity of newly synthesized, structurally modified ibuprofen and nimesulide derivatives designed to modulate PLA₂–COX-2–NF-κB axis.

Methods and Results:

Cytotoxicity was assessed in HER2-positive breast cancer cells (AU565 and SKBR3) and compared with normal dermal fibroblasts (HDF) and breast epithelial cells (MCF-12A), using WST-1 assays. Apoptosis, cell cycle distribution, caspase-3/7 activation, and ROS generation were analyzed by imaging-based assays, flow cytometry, and fluorescence methods. Gene expression of PLA2G2A and PTGS2 was quantified by qRT-PCR, and NF-κB translocation was analyzed by immunocytochemistry. Two ibuprofen triazole derivative ( D1 ) and ibuprofen thioether derivative ( D7 ) and one nimesulide derivative ( D8 ) significantly reduced cell viability in a dose-dependent manner without affecting normal cells. These derivatives induced G₀/G₁ arrest, caspase-3/7 activation, ROS reduction, and increased late apoptosis. Downregulation of PLA2G2A and PTGS2 expression and inhibition of NF-κB translocation confirmed disruption of the PLA₂–COX-2–NF-κB cascade.

Conclusion:

These findings demonstrate that structurally optimized ibuprofen and nimesulide derivatives exert dual anti-inflammatory and anticancer effects in HER2-positive breast cancer by suppressing PLA₂–COX-2–NF-κB pathway and promoting apoptotic cell death.

308

News (Medical) associated with Ibuprofen

08 Sep 2026

·www.prnewswire.com

AFT Pharmaceuticals partners with Mark Cuban Cost Plus Marketplace to bring the new non-opioid pain medication, Combogesic® to the U.S.

Prescription-strength combination of acetaminophen and ibuprofen offers non-opioid treatment option and easier access for patients with mild-to-moderate acute pain AUCKLAND, New Zealand, Sept. 8, 2026 /PRNewswire/ -- Today, AFT Pharmaceuticals announced the U.S. launch of Combogesic®, a new FDA Approved, Non-Opioid, prescription-strength combination of acetaminophen and ibuprofen developed for adult patients (over age 18) for the short-term management of mild-to-moderate acute pain. This adds the US to 66 countries around the world where this product is now available. In partnership with the Mark Cuban Cost Plus Marketplace, Combogesic brings together two of the world's most well-known pain relievers. Combogesic offers a clinically proven, FDA approved combination, providing healthcare professionals with another non-opioid treatment option for appropriate patients. For one of healthcare's most common experiences, pain management can still involve unnecessary complexity. Utilizing AFT Pharmaceuticals' Qiksolv® formulation technology, Combogesic combines prescription-strength acetaminophen and ibuprofen into a single tablet. Rather than requiring patients to coordinate multiple medicines and dosing schedules, Combogesic delivers both analgesics in one treatment. Clinical studies have demonstrated the effectiveness of Combogesic in the short-term management of mild-to-moderate acute pain. "Expectations for pain management have evolved, yet the options to treat have remained limited," said Hartley Atkinson, founder and managing director of AFT Pharmaceuticals. "Rather than inventing another molecule, we asked whether we could rethink how two of the world's most well-known pain medicines could work together in a single prescription-strength product. The result is a proven formulation that gives healthcare professionals another non-opioid treatment option for appropriate patients." That philosophy extends beyond the medicine itself. Through their partnership with the Mark Cuban Cost Plus Marketplace", AFT Pharmaceuticals is pairing pharmaceutical innovation with a world class pharmaceutical distribution model intended to improve patient health and making Combogesic accessible and affordable to patients across the United States. "We should all get excited to have more prescription, non-opioid options to combat pain" said Mark Cuban, founder of Mark Cuban Cost Plus Drug Company. "We started Mark Cuban Cost Plus Marketplace because every American should have access to safe, affordable medicines as an essential part of advancing healthcare. So ultimately patients benefit when new medications are paired with access and price transparency. That's exactly what this partnership is about. We're proud to help make Combogesic available to patients across the country." As pain management continues to evolve, healthcare professionals and patients are looking for treatment options that reflect the realities of modern care. Combogesic reflects AFT Pharmaceuticals' commitment to expanding non-opioid treatment options for appropriate patients. For more information, visit Combogesic.com. IMPORTANT SAFETY INFORMATION See full prescribing information for complete boxed warning. About AFT Pharmaceuticals AFT is a growing New Zealand-based multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories, which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs. Our business model is to develop and in-license products for our markets of Australia, New Zealand, Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland and UK, and to out-license our products to licensees and distributors in over 125 countries around the world. For more information about the company, visit our website About Mark Cuban Cost Plus Drugs The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) aims to fundamentally change the way the pharmaceutical industry operates. As a public-benefit corporation, its social mission of improving public health is just as important as the bottom line. Cost Plus Drugs transparently charges a standard markup on every drug it sells. The costplusdrugs.com online pharmacy launched in January 2022 now carries over 2,300 prescription products, delivered by mail to thousands of happy customers every day. Customers can also go to participating retail pharmacies to receive Cost Plus Drugs pricing through the Team Cuban Card. Cost Plus Drugs is working with health plans, managed-care organizations, PBMs, and self-insured employers to bring these same savings to benefit plans nationwide. Learn more at . IMPORTANT SAFETY INFORMATION Continued… Contraindications patients with known hypersensitivity to acetaminophen, ibuprofen, other NSAIDs, or to any of the excipients in this product patients with a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients. the setting of coronary artery bypass graft (CABG) surgery. Warnings and Precautions Hepatotoxicity. COMBOGESIC® contains acetaminophen and ibuprofen. Acetaminophen has been associated with cases of acute liver failure; the risk is higher in those with underlying liver disease and in those who ingest alcohol. Use in patients with hepatic impairment is not recommended. Elevations of ALT or AST have been reported in NSAID-treated patients. Cardiovascular Thrombotic Events. To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Gastrointestinal Bleeding, Ulceration, and Perforation. NSAIDs may cause serious and sometimes fatal GI adverse events at any time and without warning. Avoid use in patients at higher risk. In concomitant use with low-dose aspirin, monitor patients more closely for evidence of GI bleeding. Hypertension. NSAIDs can lead to onset of new hypertension or worsening of pre-existing hypertension, which may contribute to the increased incidence of CV events. Heart Failure and Edema. Avoid use in patients with severe heart failure unless benefits outweigh risk. Renal Toxicity and Hyperkalemia. Use in patients with renal impairment is not recommended. Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Increases in serum potassium concentration, including hyperkalemia, have been reported. Hypersensitivity and Anaphylactic Reactions. Hypersensitivity and anaphylaxis associated with ibuprofen and acetaminophen have been reported, including life-threatening anaphylaxis associated with acetaminophen. Exacerbation of Asthma Related to Aspirin Sensitivity. Patients with asthma may have intolerance to aspirin and other NSAIDs. Serious Skin Reactions. Acetaminophen or NSAIDs may cause serious skin reactions such as exfoliative dermatitis, acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), or fixed drug eruption (FDE), generalized bullous fixed drug eruption (GBFDE), which can be fatal and may occur without warning. Discontinue the use of COMBOGESIC® at the first appearance of skin rash or any other sign of hypersensitivity. Drug Rash with Eosinophilia and Systemic Symptoms (DRESS). DRESS that may be life-threatening or fatal has been reported in patients taking NSAIDs. Fetal Toxicity: Premature Closure of Fetal Ductus Arteriosus. Avoid use of COMBOGESIC® in pregnant women at about 30 weeks gestation and later. COMBOGESIC® increases the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age. Oligohydramnios/Neonatal Renal Impairment. Use of COMBOGESIC® at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. Hematologic Toxicity. Anemia has occurred in NSAID-treated patients and NSAID-treatment may increase the risk of bleeding events. Ophthalmological Effects. Blurred or diminished vision, scotomata, and/or changes in color vision have been reported with oral ibuprofen. Aseptic Meningitis. Aseptic meningitis with fever and coma has been observed in patients on oral ibuprofen. Masking of Inflammation and Fever. Activity of COMBOGESIC® in reducing inflammation, and possibly fever, may diminish signs of infections. Laboratory Monitoring. Monitor patients on long-term NSAID treatment with a CBC and a chemistry profile periodically. Adverse Reactions The most common adverse reactions (> 2%) are nausea, vomiting, headache, dizziness, somnolence, post-procedural hemorrhage, and swelling of the face. Drug Interactions Drugs That Interfere with Hemostasis. Ibuprofen and anticoagulants have a synergistic effect on bleeding. Concomitant use increases the risk of serious bleeding. Concomitant use of drugs that interfere with serotonin reuptake and an NSAID may increase the risk of bleeding. ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers. NSAIDs may diminish the antihypertensive effect of ACE inhibitors, ARBs, or Beta-Blockers. In the elderly, volume depleted, or those that have renal impairment, concomitant use with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failure. Diuretics. NSAIDs can reduce the natriuretic effect of loop diuretics and thiazides in some patients. Digoxin. Concomitant use of ibuprofen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. Lithium. NSAIDs produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. Methotrexate. Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity. Cyclosporine. Concomitant use of NSAIDs and cyclosporine may increase cyclosporine's nephrotoxicity. NSAIDS and Salicylates. Concomitant use with other NSAIDs or salicylates increases the risk of GI toxicity. Pemetrexed. Concomitant use of NSAIDs and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity. Indications and Usage COMBOGESIC® is indicated in adults (over age 18) for the short-term management of mild to moderate acute pain. To report an adverse event or product complaint, please contact us at [email protected] or call 01-248-631-4810. Adverse events may also be reported to the FDA directly at 1-800-FDA-1088 or . SOURCE AFT Pharmaceuticals 21% more press release views with Request a Demo

Drug Approval

06 Aug 2026

·www.sciencedaily.com

Major study challenges long-held fears about acetaminophen and ibuprofen use in babies

A landmark study of nearly 4,000 babies found that acetaminophen and ibuprofen were equally safe during infancy. Neither medicine was linked to eczema or bronchiolitis, and no serious side effects were caused by the drugs. Researchers will continue following the children through age six to study possible long-term effects.A major new study provides strong reassurance about the use of acetaminophen (paracetamol) and ibuprofen (Advil) during a baby's first year. Researchers found no evidence that either common pain reliever increases the risk of eczema or bronchiolitis, a respiratory illness that often affects young children. Earlier studies had raised concerns that acetaminophen (Tylenol) given during infancy might be connected to eczema, asthma, or other health conditions later in childhood. "Our study found that paracetamol and ibuprofen are incredibly safe to use in young children," says lead researcher Professor Stuart Dalziel, Cure Kids Chair of Child Health Research at Waipapa Taumata Rau, University of Auckland, and Pediatrician at Starship Children's Hospital. Dalziel notes that acetaminophen and ibuprofen are among the medicines most often prescribed or purchased over the counter for babies around the world. "These results give parents and health professionals high confidence to continue to use these important medications." Nearly 4,000 Babies Took Part The trial followed almost 4,000 babies from birth across New Zealand. Half were randomly assigned to receive acetaminophen when medication was needed for fever or pain during the first year of life. The other half were assigned to receive ibuprofen. At regular points throughout the study, parents were asked whether their children had experienced eczema, asthma symptoms, or bronchiolitis. The research team also reviewed prescription information and hospital records. The findings from the first year of follow-up have now been analyzed and published in The Lancet Child & Adolescent Health. No Significant Difference in Eczema or Bronchiolitis About 16 percent of babies in the acetaminophen group developed eczema, compared with 15 percent in the ibuprofen group. Bronchiolitis affected about five percent of children in each group. Researchers found that these differences were not statistically significant. Serious side effects were uncommon, and none were attributed to either medication. Overall, the results showed no association between acetaminophen or ibuprofen and eczema or bronchiolitis. The findings also confirmed that both medicines were safe to use during infancy. This is the first randomized controlled trial considered the gold standard for research to directly examine this question. A Long-Term Study of Childhood Health The findings are part of a larger research project called the 'Paracetamol and Ibuprofen in the Primary Prevention of Asthma in Tamariki (PIPPA Tamariki)' study. PIPPA Tamariki is the largest clinical trial involving children ever carried out in New Zealand. Participants are being monitored from birth until they reach age six. The research team plans to publish results from the children at age three, followed by additional findings when they reach age six. The broader goal is to determine whether acetaminophen use during the first year of life is connected to health conditions that cannot be diagnosed reliably until children are older. "We know that two-thirds of children who are wheezy at age three years don't develop asthma by age six," says Dalziel. "Thus we need to wait until school age to ultimately test if paracetamol in the first year of life causes asthma." Developmental conditions such as autism and attention deficit hyperactivity disorder (ADHD) also tend to be identified more accurately as children grow older. Lead author Dr. Eunicia Tan, a senior lecturer at the University of Auckland and emergency physician at Middlemore Hospital, says, "Ultimately, the study will provide important evidence regarding the link between paracetamol use and asthma, eczema, hay fever, and developmental disorders, such as autism and ADHD." The research was funded by the Health Research Council of New Zealand and Cure Kids. It was conducted by the University of Auckland and the Medical Research Institute of New Zealand, Wellington.

21 Jul 2026

·www.drugs.com

Gait Training Can Help Knee Arthritis

TUESDAY, July 21, 2026 — Changing the way you walk could offer relief from knee arthritis on par with common painkillers, clinical trial results show. Gait retraining involves making a small adjustment to the angle of your foot — a minor change that can yield major benefits, researchers wrote in The Lancet Rheumatology . People who underwent this training experienced pain relief akin to that from either over-the-counter or opioid painkillers, researchers found. The gait retraining also led to less deterioration of knee cartilage, slowing the progression of participants’ arthritis, results showed. “Especially for people in their 30s, 40s or 50s, osteoarthritis could mean decades of pain management before they’re recommended for a joint replacement,” lead researcher Scott Uhrlich , director of the Movement Bioengineering Laboratory at the University of Utah, said in a news release. “This intervention could help fill that large treatment gap.” For the new study, researchers randomly assigned 34 people with knee arthritis to undergo gait retraining, and 34 others to take “sham” training that didn’t actually change their natural gait. All participants had mild-to-moderate arthritis in the inside of their knee joint, which tends to bear more weight than the outside, researchers said. This is the most common form of knee arthritis, but the ideal foot angle for reducing load on that part of the knee differs from person to person. “We used a personalized approach to selecting each individual’s new walking pattern, which improved how much individuals could offload their knee and likely contributed to the positive effect on pain and cartilage that we saw,” Uhrlich said. In their first two visits, participants underwent MRI scans and walked on a treadmill while motion-capture cameras recorded their gait. This gave researchers the data they needed to calculate whether turning the patient’s toe inward or outward would reduce load more, as well as the most useful degree of adjustment. The personalized analysis also allowed researchers to screen out participants who wouldn’t benefit from gait training. After this initial analysis, participants returned to the lab for six weekly gait training sessions. Half were provided training intended to help their knees by changing their gait, and the other half were provided placebo training that replicated their natural gait. A year later, researchers reached out to participants to evaluate their knee health . The patients also underwent a second MRI to assess their knee structure. “The reported decrease in pain over the placebo group was somewhere between what you’d expect from an over-the-counter medication, like ibuprofen , and a narcotic, like OxyContin ,” Uhlrich said. “With the MRIs, we also saw slower degradation of a marker of cartilage health in the intervention group, which was quite exciting.” However, this program will need to be streamlined before it can be widely deployed, researchers said. The motion-capture gait assessment is time-consuming and expensive. The team hopes the training eventually could be performed in a physical therapy clinic, with people practicing what they’ve learned while walking around their neighborhood. “We and others have developed technology that could be used to both personalize and deliver this intervention in a clinical setting using mobile sensors, like smartphone video and a ‘smart shoe,’ ” Uhlrich said. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

100 Deals associated with Ibuprofen

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00126	Ibuprofen	M02AA13 R02AX02 M01AE01	DB01050

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Acute Pain	Australia	Strides Pharma Science Ltd.	30 Jul 2026
Arthritis Pain	Australia	Strides Pharma Science Ltd.	30 Jul 2026
Back Pain	Australia	Strides Pharma Science Ltd.	30 Jul 2026
Common Cold	Australia	Strides Pharma Science Ltd.	30 Jul 2026
Dysmenorrhea	Australia	Strides Pharma Science Ltd.	30 Jul 2026
Headache	Australia	Strides Pharma Science Ltd.	30 Jul 2026
Influenza, Human	Australia	Strides Pharma Science Ltd.	30 Jul 2026
Migraine Disorders	Australia	Strides Pharma Science Ltd.	30 Jul 2026
Myalgia	Australia	Strides Pharma Science Ltd.	30 Jul 2026
Sinusitis	Australia	Strides Pharma Science Ltd.	30 Jul 2026
Tension-Type Headache	Australia	Strides Pharma Science Ltd.	30 Jul 2026
Toothache	Australia	Strides Pharma Science Ltd.	30 Jul 2026
Pain, Postoperative	United States	Apotex, Inc.	23 Jan 2026
Ductus Arteriosus, Patent	European Union	Recordati Rare Diseases, Inc.	28 Jul 2004
Ductus Arteriosus, Patent	Iceland	Recordati Rare Diseases, Inc.	28 Jul 2004
Ductus Arteriosus, Patent	Liechtenstein	Recordati Rare Diseases, Inc.	28 Jul 2004
Ductus Arteriosus, Patent	Norway	Recordati Rare Diseases, Inc.	28 Jul 2004
Chronic Pain	Australia	Viatris Pty Ltd.	12 Nov 2001
Juvenile Idiopathic Arthritis	Australia	Viatris Pty Ltd.	12 Nov 2001
Osteoarthritis	United States	McNeil Consumer Healthcare	19 Sep 1974

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteoarthritis, Knee	Phase 3	United States	Overseas Pharmaceuticals Ltd.	10 Dec 2021
Osteoarthritis, Knee	Phase 3	Taiwan Province	Overseas Pharmaceuticals Ltd.	10 Dec 2021
Acute low back pain	Phase 3	Germany	Boehringer Ingelheim GmbH	20 Dec 2016
Acute low back pain	Phase 3	Russia	Boehringer Ingelheim GmbH	20 Dec 2016
Neck Pain	Phase 3	Germany	Boehringer Ingelheim GmbH	20 Dec 2016
Neck Pain	Phase 3	Russia	Boehringer Ingelheim GmbH	20 Dec 2016
Acute rise of fever	Phase 3	China	Shaanxi Synthetic Pharmaceutical Co., Ltd.	05 Feb 2015
Acute rise of fever	Phase 3	China	Xian Qinkun Pharmacy Co. Ltd.	05 Feb 2015
Mild pain	Phase 3	China	-	23 Sep 2013
Moderate pain	Phase 3	China	-	23 Sep 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02417337 (NSAID, CTgov)	Phase 2	Pulpitis \| Pain, Postoperative	185	Paracetamol (Group I)	gedeiipeht(jlfwivjqqx) = lojnfdoeaj batdiqzxak (lkhjbjhfsx, xokjtepwpe - uqueqxtksd) View more	-	25 Jun 2026
				Paracetamol+Ibuprofen (Group II)	gedeiipeht(jlfwivjqqx) = nlbadihgge batdiqzxak (lkhjbjhfsx, rxsszdsabk - kokwxnrgkg) View more
NCT05076110 (CTgov)	Phase 4	Pain	86	Oxycodone (Standard of Care Group)	afaeczaywc(txxvlquouw) = cprcjjewgt rrvioglska (ohpstquzzk, 0.2) View more	-	03 Jun 2026
				Acetaminophen+Methocarbamol+Ibuprofen+Gabapentin (Non-Opiate Pain Control Group)	afaeczaywc(txxvlquouw) = beojnykaut rrvioglska (ohpstquzzk, 0.2) View more
NCT04575519 (SMA-TB, CTgov)	Phase 2	Pulmonary Tuberculosis \| Tuberculosis, Multidrug-Resistant	426	SoC TB (Control Group)	jzljskgozd(ntyqohjntu) = yprsvegsfv jphwetpuav (kycnwwbseu, vslhwawkts - idsgmpwkoe) View more	-	01 Jun 2026
				SoC TB+ASA group (SoC TB + ASA Group)	jzljskgozd(ntyqohjntu) = cumcpqkwyc jphwetpuav (kycnwwbseu, sqlkywnopp - rzdbhnnlcd) View more
NCT06187584 (CTgov)	Phase 4	Pain \| Humeral Fractures	137	Hydrocodone/acetaminophen+Ibuprofen (Control Group (Opioid Group))	eqjsdygovi(wugtjclnpb) = prkogetcja vimjpdehmi (cmgcsyppyn, 2.05) View more	-	31 Mar 2026
				Acetaminophen+Ibuprofen (Experimental Group (Nonopioid Group):)	eqjsdygovi(wugtjclnpb) = mksklynrjx vimjpdehmi (cmgcsyppyn, 2.55) View more
NCT05640674 (CTgov)	Phase 4	Humeral Fractures \| Pain, Postoperative	29	Hydrocodone/acetaminophen+Ibuprofen (Opioid Pain Management)	zqsagyumdi(vczsbiclyo) = aplndeyjgk emihfgymib (onrdhdvwzs, 3.0) View more	-	10 Feb 2026
				Acetaminophen+Ibuprofen (Non-Opioid Pain Management)	zqsagyumdi(vczsbiclyo) = qgrqdlzedp emihfgymib (onrdhdvwzs, 1.9) View more
NCT05488847 (CTgov)	Phase 4	Shoulder Pain \| Periarthritis scapulohumeralis	83	pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Non Opioid, Multimodal Protocol)	znprbhjxca(bqqinbgcyr) = xrysmwrlzf xhgaggefaz (fndmoxifnr, 1.7)	-	10 Feb 2026
				pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Opioid Protocol)	znprbhjxca(bqqinbgcyr) = ojaligntty xhgaggefaz (fndmoxifnr, 1.6) View more
NCT04986839 (PAIR, Pubmed \| Front Pediatr)	Phase 4	Ductus Arteriosus, Patent	32	Paracetamol	kvabegytgt(zuwqygsgwa) = There were no statistically significant differences between the two groups in short- or medium-term complications of prematurity or adverse effects. upvwocamij (cdakcmemwh ) View more	Negative	02 Jan 2026
				Ibuprofen
NCT03584152 (CTgov)	Phase 2	Pain, Postoperative	159	Norco 5Mg-325Mg Tablet (Drug Arm A)	hdecghzuix(qdfzgkycxk) = aaorueinvv jpbnnvsxah (iegffokbag, 14.1) View more	-	25 Nov 2025
				Tylenol 325Mg Caplet+Ibuprofen 200 mg (Drug Arm B)	hdecghzuix(qdfzgkycxk) = hzvjtyssqt jpbnnvsxah (iegffokbag, 16.3) View more
NCT05819619 (CTgov)	Early Phase 1	Pain \| Nausea	8	misoprostol+ibuprofen+ondansetron (Standard of Care)	sqrocetsrb(irljsrsmpb) = jgvxmmxfjs ngdiaenpqm (dknyckalsq, svyuixazby - rwhychrhrf) View more	-	17 Nov 2025
				misoprostol+ibuprofen+ondansetron (Prophylactic Use)	sqrocetsrb(irljsrsmpb) = ppendahytj ngdiaenpqm (dknyckalsq, fcvufzcfxj - vzrmaumhzg) View more
NCT02763059 (CBDIPPCFSIP, CTgov)	Phase 4	Pain, Postoperative	132	Ibuprofen (Group 1- Received Ibuprofen (N=39))	vxmzjtisfl(ipmtjzsslf) = egpedlyfrn ceizesdxsz (xzvwfjwhoy, lyzdkpvbsn - noppkorfeg) View more	-	29 Oct 2025
				Dexamethasone (Group 2- Received Dexamethasone (N=43))	vxmzjtisfl(ipmtjzsslf) = iwtftacfef ceizesdxsz (xzvwfjwhoy, vcibtwbuur - prdqrtvxst) View more